Recent Updates
Recently added Catalysts
TNGX Positive Sentiment

Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference

Key Takeaway: Tango Therapeutics announced that CEO Malte Peters will participate in Guggenheim's 3rd Annual Healthcare Innovation Conference on November 10, 2026. The event will feature a fireside chat and will be accessible via a live webcast. The company focuses on targeted therapies for cancer, particularly PRMT5-targeted treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • CEO Malte Peters will present at a major healthcare conference.
  • Tango Therapeutics announced a live webcast for investors.
  • The company highlighted its focus on genetic vulnerabilities in cancer.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+42%
120-day peak, hindsight
Typical move
4.6%
average across 7 past catalysts
Cash runway
~76 mo
Low dilution risk
Lead asset
TNG462
Phase 1 · PDAC

Full Press Release Details

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at Guggenheim’s 3 rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 at 8:00 AM EST.
The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer. Using an approach that focuses on genetic vulnerabilities in cancer, Tango Therapeutics is pursuing PRMT5-targeted therapies designed to address pancreatic and other forms of cancer while sparing healthy normal tissues. For more information, please visit www.tangotx.com .

Frequently Asked Questions

When is the Guggenheim Healthcare Innovation Conference?

The conference is scheduled for November 10, 2026.

Who will represent Tango Therapeutics at the conference?

Malte Peters, CEO of Tango Therapeutics, will represent the company.

How can I watch the conference presentation?

The presentation will be available via a live webcast on the company's website.

What is Tango Therapeutics focused on?

The company focuses on targeted therapies for cancer, particularly PRMT5-targeted treatments.

Last updated: Nov 3, 2026